Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, January 2nd.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
Other equities research analysts also recently issued reports about the stock. Canaccord Genuity set a $11.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 24th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 15th. ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Vetr upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.64 target price for the company in a research report on Wednesday, September 13th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Aurinia Pharmaceuticals has an average rating of “Buy” and an average price target of $10.79.
Shares of Aurinia Pharmaceuticals (AUPH) traded up $0.09 during midday trading on Tuesday, reaching $5.35. 1,043,662 shares of the company’s stock traded hands, compared to its average volume of 1,000,288. The company has a market capitalization of $441.70, a P/E ratio of -4.05 and a beta of 2.35. Aurinia Pharmaceuticals has a twelve month low of $2.30 and a twelve month high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The firm’s revenue was up .0% compared to the same quarter last year. equities research analysts predict that Aurinia Pharmaceuticals will post -1.05 EPS for the current year.
Large investors have recently bought and sold shares of the business. FMR LLC lifted its holdings in Aurinia Pharmaceuticals by 0.3% during the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock worth $35,969,000 after buying an additional 19,200 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Aurinia Pharmaceuticals by 357.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock worth $5,373,000 after buying an additional 684,816 shares in the last quarter. Alyeska Investment Group L.P. lifted its holdings in Aurinia Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock worth $4,273,000 after buying an additional 12,171 shares in the last quarter. Balyasny Asset Management LLC lifted its holdings in Aurinia Pharmaceuticals by 66.7% during the 2nd quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $3,065,000 after buying an additional 200,000 shares in the last quarter. Finally, AWM Investment Company Inc. increased its position in shares of Aurinia Pharmaceuticals by 17.5% in the 2nd quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 52,500 shares during the last quarter. Institutional investors own 28.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/aurinia-pharmaceuticals-auph-lowered-to-sell-at-zacks-investment-research.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.